Canaccord Genuity Reiterates Buy on Adicet Bio, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman has reiterated a Buy rating on Adicet Bio (NASDAQ:ACET) and maintained a $19 price target.
March 20, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman reiterated a Buy rating on Adicet Bio with a $19 price target.
The reiteration of a Buy rating and maintenance of a $19 price target by a reputable analyst suggests a positive outlook for Adicet Bio, likely leading to increased investor confidence and potential upward movement in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100